Explore the most recent oncology treatments approved in the last year, marking a milestone in the fight against cancer. This comprehensive guide details innovations in targeted therapies, immunotherapies, and new drugs that are transforming patient care. Stay up-to-date with crucial medical advancements offering new hope and treatment options for various malignancies. Discover how research and development are paving the way for a future with better patient outcomes.
Approved for BRCA2-mutated metastatic castration-sensitive prostate cancer
(+4)
Akeega has received FDA approval as an innovative treatment for metastatic prostate cancer with BRCA mutations. Its unique formulation combines two medicines in one tablet, offering a targeted and simplified therapeutic option for patients with castration-sensitive or castration-resistant prostate cancer.
First all-oral, fixed-duration regimen
(+2)
Acalabrutinib has received significant approvals in the past year for the treatment of previously untreated mantle cell lymphoma, both in the US and EU, in combination with chemoimmunotherapy. Its use with venetoclax has also been approved as the first all-oral, fixed-duration combination for chronic lymphocytic leukemia. These approvals represent important advancements in therapeutic options for patients with these oncological diseases.
Granted orphan drug designation
(+3)
CK0804 received FDA orphan drug designation in January 2026 for the treatment of myelofibrosis, positioning it as a significant advancement in oncology. This investigational Treg cell therapy offers new hope for patients with limited treatment options, addressing an unmet medical need within the last year.
Granted accelerated approval by FDA
(+1)
Sevabertinib received accelerated FDA approval in January 2026 for the treatment of non-squamous non-small cell lung cancer. This drug represents a significant advancement by offering a new therapeutic option for patients with HER2-mutant disease, demonstrating notable tumor shrinkage and prolonged disease control.
Received orphan drug designation from FDA and EMA
(+3)
CPI-008 received Orphan Drug Designation from the FDA and EMA in January 2026, marking it as a significant advancement in oncology treatment. This imaging drug enhances margin detection for pancreatic cancer during surgery, promising improved patient outcomes. Its ability to improve cancer tissue visualization is crucial for complete tumor removal.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Selumetinib (Koselugo) received FDA approval in November 2025 for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. This approval, based on the Phase 3 KOMET trial results, represents a crucial advancement in the oncological treatment of this rare disease. Furthermore, in September 2025, its approval was expanded to include granule and capsule formulations for pediatric patients one year of age and older, solidifying its impact over the past year.
Approved for metastatic castration-sensitive prostate cancer
(+3)
Nubeqa received a key FDA approval on June 3, 2025, for metastatic castration-sensitive prostate cancer (mCSPC), representing a significant advancement in treatment options. This approval expands its use, offering a new combination therapy with docetaxel for patients with this aggressive form of cancer. Its efficacy in delaying disease progression and improving survival makes it a notable oncology treatment approved in the last year.
Significant milestone for advanced ovarian cancer patients
(+4)
Olaparib (Lynparza) has recently received approvals for various oncological indications, including ovarian, prostate, and breast cancer, representing a significant advancement in targeted therapy. Its mechanism of action as a PARP inhibitor exploits DNA damage response deficiencies in cancer cells, offering a vital treatment option for patients with specific mutations like BRCA.
Approved for BRCA mutation-associated metastatic castration-resistant prostate cancer
(+1)
Rucaparib (Rubraca) was approved by the FDA on December 17, 2025, for BRCA variant-associated, metastatic, castration-resistant prostate cancer. This approval represents a significant advancement in treatment options for patients with this specific condition, offering a new targeted therapy.
Granted traditional approval by FDA
Tarlatamab (Imdelltra™) received FDA approval in the last year for the treatment of extensive-stage small cell lung cancer, providing a crucial new therapeutic option. This drug represents a significant advancement in oncological immunotherapy, improving survival for patients with progressive disease after chemotherapy.
Trastuzumab deruxtecan has received multiple FDA approvals in the last year for treating a wide variety of cancers, including HER2-low and HER2-positive breast cancer, and HER2-mutant non-small cell lung cancer. Its innovative mechanism of action, which delivers chemotherapy directly to tumor cells, has demonstrated significant improvement in progression-free and overall survival in patients with metastatic cancer.
Sacituzumab govitecan has recently received approvals for the treatment of metastatic triple-negative breast cancer and advanced urothelial cancer, providing a new therapeutic option. Its targeted mechanism of action represents a significant advancement in oncology, improving prospects for patients with limited treatment options.
The FDA approval of Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in September 2025 marks a significant milestone in oncology. This new subcutaneous formulation offers a more convenient administration alternative for patients with multiple solid tumor types, enhancing the cancer treatment experience.
This ranking has been developed to highlight significant advancements in oncology treatments approved or granted orphan drug designation in the last year. Our goal is to provide a clear and concise overview of the innovations impacting the field of oncology.